| 4.23 0.36 (9.3%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.68 |
1-year : | 6.64 |
| Resists | First : | 4.86 |
Second : | 5.68 |
| Pivot price | 3.95 |
|||
| Supports | First : | 3.95 |
Second : | 3.39 |
| MAs | MA(5) : | 4.14 |
MA(20) : | 3.84 |
| MA(100) : | 4.31  |
MA(250) : | 7.34 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 38.2 |
D(3) : | 51.1 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 32 | Low : | 1.83 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SNGX ] has closed below upper band by 25.1%. Bollinger Bands are 62.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.46 - 4.48 | 4.48 - 4.5 |
| Low: | 3.79 - 3.82 | 3.82 - 3.85 |
| Close: | 4.18 - 4.23 | 4.23 - 4.27 |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Thu, 03 Oct 2024
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development - Research Tree
Thu, 03 Oct 2024
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… - Zacks Small Cap Research
Thu, 03 Oct 2024
Soligenix Announces Partnership with Sterling Pharma Solutions - StockTitan
Mon, 16 Sep 2024
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 - StockTitan
Fri, 16 Aug 2024
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Tue, 13 Aug 2024
SNGX: Phase 3 Trial of HyBryte™ in CTCL to Initiate in 2H24… - Zacks Small Cap Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 2.28e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 106 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.77e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -74 % |
| Return on Assets (ttm) | 495 % |
| Return on Equity (ttm) | -41.1 % |
| Qtrly Rev. Growth | 494620 % |
| Gross Profit (p.s.) | -53.75 |
| Sales Per Share | -82.62 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.7 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 3.45 |
| Dividend | 0 |
| Forward Dividend | 103240 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|